LIGAND PHARMACEUTICALS INCORPORATED Operating Lease, Expense
LIGAND PHARMACEUTICALS INCORPORATED (LGND) reported Operating Lease, Expense of $900.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-02-27
- LIGAND PHARMACEUTICALS INCORPORATED operating lease, expense for the quarter ending 2019-12-31 was $500.00K.
- LIGAND PHARMACEUTICALS INCORPORATED operating lease, expense for the quarter ending 2019-09-30 was $500.00K.
- LIGAND PHARMACEUTICALS INCORPORATED operating lease, expense for the quarter ending 2019-06-30 was $500.00K.
- LIGAND PHARMACEUTICALS INCORPORATED operating lease, expense for the quarter ending 2019-03-31 was $600.00K.
- LIGAND PHARMACEUTICALS INCORPORATED operating lease, expense for fiscal 2025 was $900.00K, a 30.77% decline from fiscal 2024.
- LIGAND PHARMACEUTICALS INCORPORATED operating lease, expense for fiscal 2024 was $1.30M, a 7.14% decline from fiscal 2023.
- LIGAND PHARMACEUTICALS INCORPORATED operating lease, expense for fiscal 2023 was $1.40M, a 100.00% increase from fiscal 2022.
- LIGAND PHARMACEUTICALS INCORPORATED operating lease, expense for fiscal 2022 was $700.00K, a 30.00% decline from fiscal 2021.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month | Operating Lease, Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $900.00K 10-K · filed 2026-02-27 | ||||
| 2024-12-31 | $1.30M 10-K · filed 2026-02-27 | ||||
| 2023-12-31 | $1.40M 10-K · filed 2026-02-27 | ||||
| 2022-12-31 | $700.00K 10-K · filed 2024-02-29 | ||||
| 2021-12-31 | $1.00M 10-K · filed 2023-02-28 | $2.60M 10-K · filed 2022-02-28 | |||
| 2020-12-31 | $2.10M 10-K · filed 2022-02-28 | ||||
| 2019-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $1.00M derived: sum of 2 quarters · filed 2021-02-24 | $1.50M derived: sum of 3 quarters · filed 2021-02-24 | $2.10M 10-K · filed 2021-02-24 | |
| 2019-09-30 | $500.00K 10-Q · filed 2019-11-08 | $1.00M derived: sum of 2 quarters · filed 2019-11-08 | $1.60M 10-Q · filed 2019-11-08 | ||
| 2019-06-30 | $500.00K 10-Q · filed 2019-08-08 | $1.10M 10-Q · filed 2019-08-08 | |||
| 2019-03-31 | $600.00K 10-Q · filed 2019-05-09 |